Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Fresenius Kabi and TQ Therapeutics announced a strategic‑development agreement granting Fresenius Kabi exclusive rights to...
BMS’s Mavacamten Shows Significant LVOT Reduction in First Adolescent oHCM Phase III Study
Bristol‑Myers Squibb (BMS, NYSE: BMY) announced positive topline results from the Phase 3 SCOUT‑HCM study evaluating mavacamten...
WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development
WuXi Biologics (HKG: 2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) global exclusive...
ABM Therapeutics Licenses MEK1/2 Inhibitor ABM‑168 to Mosaica Medicines for Global Development
ABM Therapeutics Inc. announced a licensing agreement granting Mosaica Medicines global rights to ABM‑168, an...
WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA, announced its...
Fosun Kairos Secures Greater China Rights to ElpasBio’s AlloJoin for Knee Osteoarthritis
Fosun Kairos, a joint venture between Fosun Pharmaceutical (SHA: 600196, HKG: 2196) and Gilead Sciences/Kite...
Sino Biopharmaceutical Buys Hygieia Pharma for up to RMB 1.2 B, Adding siRNA Platform for Chronic Diseases
Sino Biopharmaceutical Ltd. (HKG: 1177) announced it has agreed to acquire a 100 % equity stake in...
NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation
China’s National Healthcare Security Administration (NHSA) this week released the Series of Guidelines for Real‑World...
J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced positive topline results from the Phase 3 MajesTEC‑9 study of...
Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
Immvira Bioscience Inc. filed for an initial public offering on the Hong Kong Stock Exchange...
Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on...
Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced the launch of an AI-powered R&D platform focused...
QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509) announced that its US partner Caldera Therapeutics, Inc. has...
Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the U.S. Food and Drug Administration (FDA)...
WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
WuXi Biologics (HKG: 2269) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has...
NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
NVIDIA Corporation and Eli Lilly and Company (NYSE: LLY) announced a first‑of‑its‑kind AI co‑innovation lab to...
AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
AstraZeneca plc (AZ, NASDAQ: AZN) announced the acquisition of Modella AI, a leader in artificial intelligence...
Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...
WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
WuXi AppTec (SHA: 603259, HKG: 2359) released preliminary 2025 performance data, projecting full‑year revenue of...
Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation...